A Phase 2 trial of RAYALDEE in in dialysis patients with secondary hyperparathyroidism (SHPT)

Trial Profile

A Phase 2 trial of RAYALDEE in in dialysis patients with secondary hyperparathyroidism (SHPT)

Planning
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Calcifediol (Primary)
  • Indications Hyperparathyroidism; Renal failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2017 According to an OPKO Health media release, the company anticipates initiating this trial during the 4Q 2017.
    • 06 Jul 2017 New trial record
    • 09 May 2017 According to an OPKO Health media release, the company anticipates initiating this trial during the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top